Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV001644778 | SCV000843519 | likely benign | not specified | 2024-02-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001049336 | SCV001213382 | likely benign | Spastic paraplegia | 2024-11-05 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV003480803 | SCV004226405 | uncertain significance | not provided | 2023-02-13 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001274918 | SCV001459472 | uncertain significance | Charlevoix-Saguenay spastic ataxia | 2020-09-16 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004748913 | SCV005353849 | likely benign | SACS-related disorder | 2024-08-11 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |